Scientific Online Resource System

Annual for Hospital Pharmacy

Perspectives For Target Therapy In The Treatment Of Malignant Neoplasms Of The Urinary Bladder

Olga Antonova, Boris Mladenov, Simeon Rangelov, Chavdar Slavov, Draga Toncheva

Abstract

The etiology, pathogenesis and treatment of malignant neoplasms of the bladder still address a number of issues. Several biomarkers have been identified showing differences in the molecular image of invasive and non-invasive uroepithelial carcinoma. These biomarkers are part of the factors responsible for the large variation in treatment even in tumors with the same histological diagnosis. Currently, standard systemic therapy includes various cytotoxic chemotherapy regimens and is based mainly on histological evaluation and tumor progression. Since May 2016, target therapy has been approved for the first time in the treatment of oncological bladder disease. Target therapy is used to stop the growth and spread of cancer cells by suppressing activated signaling pathways - most often fibroblast, epidermal and endothelial growth factor pathways. The choice of „ the right“ drug is largely based on the molecular genetic diagnosis of the tumor and the presence of specific biomarkers indicating the applicability of one or another drug.
Significant progress has been made in the era of molecular diagnosis and target therapy, which leads to prolonged survival and improved quality of life of oncology patients. In this article, we examine the potential and existing options for the use of precision therapy in patients with uroeptithelial tumors.

Keywords

uroepithelial tumors, target therapy, precision medicine

Full Text


References

Mohammed AA, El-Tanni H, El-Khatib HM, Mirza AA, Mirza AA, Alturaifi TH. Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention. Oncology reviews. 2016;10(2):320.

Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, et al. Focus on bladder cancer. Cancer cell. 2004;6(2):111-6.

McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, et al. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urologic oncology. 2010;28(4):429-40.

Millis SZ, Bryant D, Basu G, Bender R, Vranic S, Gatalica Z, et al. Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clinical genitourinary cancer. 2015;13(1):e37-49.

Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nature reviews Cancer. 2015;15(1):25-41.

Lamy A, Gobet F, Laurent M, Blanchard F, Varin C, Moulin C, et al. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. The Journal of urology. 2006;176(6 Pt 1):2686-9.

Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, et al. p53 predictive value for pT1-2 N0 disease at radical cystectomy. The Journal of urology. 2009;182(3):907-13.

Cairns P, Proctor AJ, Knowles MA. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene. 1991;6(12):2305-9.

Ishikawa J, Xu HJ, Hu SX, Yandell DW, Maeda S, Kamidono S, et al. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer research. 1991;51(20):5736-43.

Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. British journal of cancer. 1995;71(4):831-5.

Xu HJ, Cairns P, Hu SX, Knowles MA, Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. International journal of cancer Journal international du cancer. 1993;53(5):781-4.

Gan X, Lin X, He R, Lin X, Wang H, Yan L, et al. Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis. Disease markers. 2016;2016:5259602.

Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, et al. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. The American journal of pathology. 1999;155(1):105-13.

Антонова ОС. Характеризиране на молекулни промени в преходноклетъчни уроепителни карциноми и определяне на антитуморен ефект на хемоцианини: Медицински Университет-София; 2015.

Gust KM, McConkey DJ, Awrey S, Hegarty PK, Qing J, Bondaruk J, et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Molecular cancer therapeutics. 2013;12(7):1245-54.

Milowsky MI, Dittrich C, Duran I, Jagdev S, Millard FE, Sweeney CJ, et al. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014;50(18):3145-52.

Ineichen GB, Rothlisberger R, Johner KF, Seiler R. Different stages in drug development for muscle-invasive bladder cancer. Translational andrology and urology. 2017;6(6):1060-6.

https://www.onclive.com/conference-coverage/gu-2018/erdafitinib-elicits-high-response-rates-in-fgfr-positiveurothelial-cancer. [cited 2018 26 August].

Rolfo C, Passiglia F, Ostrowski M, Farracho L, Ondoichova T, Dolcan A, et al. Improvement in lung cancer outcomes with targeted therapies: an update for family physicians. Journal of the American Board of Family Medicine : JABFM. 2015;28(1):124-33.

Pirker R. What is the best strategy for targeting EGF receptors in non-small-cell lung cancer? Future oncology. 2015;11(1):153-67.

Petrylak DP, Tangen CM, Van Veldhuizen PJ, Jr., Goodwin JW, Twardowski PW, Atkins JN, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU international. 2010;105(3):317-21.

Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ, Cancer, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2009;20(6):1074-9.

Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU international. 2010;106(3):349-54.

Kamat AM. Commentary on “Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.” Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania, Philadelphia, PA: J Clin Oncol 2012;30(28):3545-51 [Epub 2012 Aug 27]. Urologic oncology. 2013;31(5):719.

Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(28):3545-51.

Bladder cancers respond to EGFR inhibitors. Cancer discovery. 2014;4(9):980-1.

Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, et al. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine. 2016;12:105-17.

Tsai YC, Ho PY, Tzen KY, Tuan TF, Liu WL, Cheng AL, et al. Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells. Molecular cancer therapeutics. 2015;14(3):810-20.

Mooso BA, Vinall RL, Mudryj M, Yap SA, deVere White RW, Ghosh PM. The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. The Journal of urology. 2015;193(1):19-29.

Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. British journal of cancer. 1991;63(4):601-8.

Gardiner RA, Samaratunga ML, Walsh MD, Seymour GJ, Lavin MF. An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer. Urological research. 1992;20(2):117-20.

Lipponen P. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer. 1993;29A(5):749-53.

Burris HA, 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. The oncologist. 2004;9 Suppl 3:10-5.

de Martino M, Zhuang D, Klatte T, Rieken M, Roupret M, Xylinas E, et al. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer biology & therapy. 2014;15(9):1239-47.

Wulfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009;115(13):2881-90.

Narayan V, Mamtani R, Keefe S, Guzzo T, Malkowicz SB, Vaughn DJ. Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer. Cancer research and treatment : official journal of Korean Cancer Association. 2016;48(3):1084-91.

Chaudhary U GA, Brisendine A Phase II trial of neoadjuvant GC and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29:abstract 276.

Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010;76(4):923-6.

Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, et al. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(13):1500-9.

Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urologic oncology. 2009;27(4):391-9.

Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(8):1373-9.

Mullane SA, Bellmunt J. Cancer immunotherapy: new applications in urologic oncology. Current opinion in urology. 2016;26(6):556-63.

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287&audience=consumer. [cited 2018 25 August].

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394&audience=consumer. [cited 2018 25 August].

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3. [cited 2018 25 August].

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118. [cited 2018 25 August].




DOI: http://dx.doi.org/10.14748/.v4i1.5509

Refbacks

Article Tools
Email this article (Login required)
|